MG
KPTI icon

Michael Gelband’s Karyopharm Therapeutics KPTI Stock Holding History

Michael Gelband’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Buy
+26,582
New +$231K ﹤0.01% 1391
2023
Q4 		– Sell
-93,170
Closed -$1.87M – 1774
2023
Q3 		$1.87M Sell
93,170
-65,660
-41% -$1.47M 0.02% 697
2023
Q2 		$4.26M Buy
+158,830
New +$6.84M 0.03% 509
2023
Q1 		– Sell
-73,742
Closed -$3.76M – 1950
2022
Q4 		$3.76M Buy
73,742
+26,590
+56% +$1.84M 0.05% 429
2022
Q3 		$3.86M Buy
47,152
+4,086
+9% +$305K 0.05% 500
2022
Q2 		$2.91M Buy
43,066
+41,767
+3,215% +$3.83M 0.04% 625
2022
Q1 		$144K Sell
1,299
-5,961
-82% -$743K ﹤0.01% 1966
2021
Q4 		$700K Buy
7,260
+5,265
+264% +$525K 0.01% 1247
2021
Q3 		$174K Buy
1,995
+187
+10% +$19.4K ﹤0.01% 1811
2021
Q2 		$280K Buy
1,808
+81
+5% +$11.8K ﹤0.01% 1783
2021
Q1 		$273K Buy
+1,727
New +$364K ﹤0.01% 1731
2020
Q4 		– Sell
-1,513
Closed -$331K – 2179
2020
Q3 		$331K Buy
+1,513
New +$370K 0.01% 1234
2020
Q2 		– Sell
-1,917
Closed -$552K – 1909
2020
Q1 		$552K Buy
+1,917
New +$529K 0.03% 452
2019
Q4 		– Sell
-6,600
Closed -$952K – 1712
2019
Q3 		$952K Buy
6,600
+4,880
+284% +$662K 0.03% 404
2019
Q2 		$155K Buy
+1,720
New +$138K 0.01% 971

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Michael Gelband's KPTI Position: Q2 2026 in Review

Michael Gelband opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 26,582 shares worth $260K. The stake represents ﹤0.01% of the portfolio and ranks #1391 among its holdings. This is a return to the name: Michael Gelband previously reported a position in KPTI as recently as Q3 2023.

Michael Gelband first reported a position in KPTI in Q2 2019 and has held it in 15 quarters since. The position peaked at $4.26M in Q2 2023. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Michael Gelband held 26,582 shares of Karyopharm Therapeutics worth $260K as of Q2 2026.
  • Karyopharm Therapeutics was a new Michael Gelband position in Q2 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1391 holding.
  • Michael Gelband first reported a position in Karyopharm Therapeutics in Q2 2019 and has held it in 15 quarters since.
  • Michael Gelband's Karyopharm Therapeutics position peaked at $4.26M in Q2 2023.
  • 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.